LETTERS TO THE EDITOR Antinuclear and Antinucleolar Antibodies in
Patients with Scleroderma-Polymyositis Overlap Syndrome SIR-Polymyositis-scleroderma overlap syndromes are uncommon. TufTanelli and Winkelmann [1] reported 36 out of 727 scleroderma patients (5%) with features of these two conditions, and used the term 'sclerodermatomyositis'. Mimori [2] found 27 out of 240 scleroderma patients (11%) who fulfilled the criteria for both progressive systemic sclerosis (PSS) and polymyositis/dermatomyositis (PM/DM). Wolfe et al. [3] described autoantibodies, characteristic to patients with PSS/PM overlap, designated anti-PM-1; Reichlin et al. [4] characterized the anti-PM-Scl antibody which is strongly associated with the PSS/PM overlap syndrome. The prevalences of anti-PmScl antibodies have been reported as 8% in myositis sera and from 2 to 5% in scleroderma sera, and 24% in PM/Scl overlap sera [5, 6] .
The number of reported patients with PSS/PM overlap is small. We wanted to evaluate the prevalence of PSS/PM overlap syndrome among scleroderma patients, and to find out what autoantibodies are associated with this clinical syndrome. Of 224 consecutive patients with systemic sclerosis treated in the Department of Rheumatology, Xavier Bichat School of Medicine, 18 patients had features of PSS/PM overlap. The patient charts were evaluated for clinical data, and the features of scleroderma and myositis were evaluated systematically for each patient. All patients fulfilled the ARA criteria for systemic sclerosis [7] . The classification into diffuse and limited systemic sclerosis was made according to LeRoy et al. [8] . For the diagnosis of PM/DM, the criteria proposed by Bohan and Peter [9] were used. The patient sera were tested for ANA by indirect IF using slides of HEp-2 cells, double immunodiffusion using rabbit thymus extract as antigen, and Western blotting using a HeLa cell nuclear extract. Reference anti-PmScl-positive serum was a gift from Dr Humbel (Luxemburg) and anti-Ku-positive serum was generously given by Dr Reeves (Chapel Hill, NC, USA).
In this study, the prevalence of PSS/PM overlap syndrome among patients with systemic sclerosis was 8%. There were 18 PSS/PM overlap patients, 14 female and four male. At the time of diagnosis of the PSS/PM overlap syndrome, their mean age was 46 yr (range 17-68 yr). Table I lists their major clinical and laboratory findings. The most frequently noted ANA patterns were antinucleolar and homogeneous staining patterns. Among sera with antinucleolar antibodies, five were positive for anti-PmScl. Other less prevalent specificities were anti-UlRNP, anti-SS-B, anti-Jo-1 and anti-Ku. All five anti-PmScl-positive patients were female and they all had limited type systemic sclerosis. There was a prominent muscle weakness in all of our PSS/PM overlap patients, and confirmatory studies were made on the basis of clinical suspicion. Muscle biopsy was performed on 10 patients and EMG on eight patients. All of our PSS/PM patients had elevated muscle enzymes (creatine kinase). Typical cutaneous findings of DM were noted in three (3/5) anti-PmSclpositive patients and in eight (44%) PSS/PM overlap patients. The PSS/PM patients in our study came from various areas of the country, and for several patients the treatment continued in their home towns. Thus, follow-up data are not available on many of these patients, and we could not evaluate the course and prognosis of the PSS/PM overlap syndrome in this study.
We found anti-PmScl antibodies in 28% of patients with PSS/PM overlap syndrome, which is comparable to earlier studies [5, 6] . Kuwana et al. [10] reported in a large study comparing three racial groups that anti-Pm-Scl antibodies were found exclusively in Caucasian patients, which reflects the importance of genetic factors in autoantibody expression. The PSS/PM patients do not seem to have consistent and uniform immunological features. The overall prognosis of the PSS/PM overlap patients seems to be good, but the clinical and prognostic significance of the PSS/PM-associated antibodies still needs to be evaluated. Antiiieutropb.il Cytoplasmic Antibody-Positive Polyarthritis Associated with Minocycline Therapy SIR-Long-term minocycline therapy has been implicated in the induction of antinuclear antibody (ANA)-positive autoimmune disease: systemic lupus erythematosus-like syndrome and chronic active hepatitis [1] [2] [3] [4] [5] . Drug-induced lupus was first described in patients receiving the anti-hypertensive agent hydralazine [6] . Hydralazine can also provoke a systemic vascuh'tis with a rapidly progressive glomerulonephritis associated with autoantibodies directed against components of the neutrophil cytoplasm with specificity for lactoferrin [7] . Antibodies against lactofemn have rarely been described in other systemic vasculitic syndromes.
A 32-yr-old male retail manager who had taken minocycline 100 mg daily for 1 yr presented with a 3 month history of sudden onset and progressive fever, malaise, early morning stiffness, symmetrical polyarthritis and weight loss (6 kg). His symptoms were so severe that he was unable to work. Examination revealed low-grade fever (37.8°C) and synovial proliferation of wrists, knees and ankles. There was no evidence of skin, respiratory, renal or neurological disease. Investigations showed blood haemoglobin 11.7 g/dl, ESR lOlmm/h, CRP 129mg/l (<30mg/l) and serum IgG 20.1 g/1 (<16.1g/l). Antineutrophil cytoplasmic antibodies (ANCA) with specificity for lactoferrin were detected by ELISA and indirect immunofluorescence. Rheumatoid factor and ANA were negative. Non-steroidal anti-inflammatory drugs were ineffective in controlling his symptoms. Withdrawal of minocycline therapy resulted in a dramatic and complete resolution of symptoms. He returned to work 6 weeks later. Blood haemoglobin, ESR, CRP and IgG were normal, and ANCA was negative.
To our knowledge, this is the first description of minocycline-related ANCA-positive polyarthritis. The dramatic reversal of clinical and laboratory features implicates minocycline as the causative agent. Our findings support the view that minocycline has a propensity for causing a variety of immunologically mediated events. Antibody Levels to Clostridium perfiringens ami Response to Sulphasalazine Sm-Previously, we studied 31 patients with active rheumatoid arthritis during treatment with the disease-modifying drug sulphasalazine (SASP) to establish whether changes in faecal flora (in particular Clostridium perfringens) correlated with response to the drug [1] . In addition, its effects on serum antibody levels to bacterial antigens in relation to response were studied. For the purposes of this study, response was determined based on the percentage change in two clinical (early morning stiffness and articular index) and two biochemical (plasma viscosity and CRP) parameters between weeks 0 and 16 of the study. Each patient was given a signed rank according to the percentage change for each parameter, a positive rank indicating improvement. The four individual ranks given to each patient for each parameter were then summed to give an overall degree of response [1] . We found that although SASP caused a decrease in faecal counts of C. perfringens, this was not mirrored by a corresponding decrease in serum antibody levels to its antigens nor did it correlate with response. This indicated that the mode of action of SASP in RA was not via its antibacterial action, as has been suggested [2] . However, we did find that antibody levels to an acetone extract of C. perfringens were significantly lower in those patients who had been classified as being good responders to drug treatment than those who had
